Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05243355
Other study ID # SMA-NSCLC-005
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 3, 2021
Est. completion date December 3, 2024

Study information

Verified date December 2021
Source Qilu Hospital of Shandong University
Contact Lian Liu, Doctor
Phone 18560082903
Email tounao@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Envafolimab combined with standard platinum containing dual drug chemotherapy and Recombinant Human Endostatin in patients with advanced (stage IIIB-IV) squamous non-small cell lung cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 46
Est. completion date December 3, 2024
Est. primary completion date December 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Signed written informed consent; - Aged 18-75 years old; - Histologically or cytologically confirmed, locally advanced (Stage IIIB/C) not amenable to curative surgery or radiotherapy, or metastatic/recurrent (Stage IV) squamous NSCLC according to American Joint Committee on Cancer, 8th Edition; - At least 1 measurable lesion as defined by RECIST v1.1; - ECOG performance status 0-1; - No systematic antitumor treatment for advanced / metastatic diseases has been received in the past; - Life expectancy sup 3 months; - Adequate organ function; - For female subjects of childbearing age, urine or serum pregnancy test shall be conducted 3 days before receiving the first study drug administration, and the result is negative; - The subject and the subject's sexual partner need to use a medically approved contraceptive measure during the study treatment period and within 6 months after the end of the study treatment period. Exclusion Criteria: - Histology was non squamous cell NSCLC. Mixed cell types must distinguish the dominant cell morphology (squamous cell carcinoma components > 50% can be included in the group); If there are small cell carcinoma, neuroendocrine carcinoma and sarcoma, they can not be included in the group; - EGFR sensitive mutations or ALK rearrangements; - Imaging (CT or MRI) showed that the tumor invaded large blood vessels or it was judged that the tumor was very likely to invade important blood vessels and cause fatal bleeding during the follow-up study; - Concurrent participation in another clinical trial; - Have previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or co inhibit T cell receptors (e.g., CTLA-4, OX-40, CD137); - Received Chinese patent medicine with anti-tumor indications or drugs with immunomodulatory effect (thymosin, interferon, interleukin, etc.) within 2 weeks, or major surgical treatment within 3 weeks before the first administration; - There are active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal obstruction and peritoneal metastasis that need clinical intervention; - Grade III-IV congestive heart failure (New York Heart Association classification), poorly controlled and clinically significant arrhythmia; - Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before enrollment; - Known allergic reactions to PD-1/L1 monoclonal antibodies, taxanes, cisplatin or carboplatin, recombinant human endostatin active ingredients and or any excipients; - Patients requiring long-term systemic use of corticosteroids; - Symptomatic central nervous metastasis; - Active infection requiring treatment or systemic anti infective drugs used within one week before the first administration; - Not fully recovered from toxicity and/or complications caused by any intervention before starting treatment (i.e. = grade 1 or reaching baseline, excluding fatigue or hair loss); - Known HIV infection; - Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number detected greaterthan the upper limit of normal value in the laboratory of the research center); - Active HCV infected; - Live vaccine was administered within 30 days before the first administration; - Pregnant or lactating women; - Medical history or disease evidence, abnormal treatment or laboratory test values that may interfere with the test results, prevent the subjects from participating in the whole study, or other situations that the researchers believe are not suitable for inclusion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
"Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin"
Envafolimab: 300 mg,D1,Q3W,until PD or intolerable toxicity Chemotherapy: Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w; Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles in total. Recombinant Human Endostatin:210mg,CIV 72h,d1-3,Q3W,4-6 cycles in total.

Locations

Country Name City State
China Qilu hospital of Shandong univertisy Jinan Shandong
China Shandong Cancer Hospital Jinan

Sponsors (1)

Lead Sponsor Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 1 year PFS rate 12-month progression free survival in ITT population 12 months after the last subject participating in
Secondary ORR The proportion of subjects with complete response (CR) and partial response (PR) in total subjects 24 months after the last subject participating in
Secondary DOR DoR (per RECIST 1.1) is defined as the time from the date for first documented response of complete response (CR) or partial response (PR) to the date of first documented of disease progression or death, whichever occurs first. 24 months after the last subject participating in
Secondary PFS Progression-free survival (PFS per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first 24 months after the last subject participating in
Secondary OS OS is defined as the time from the starting date of study drug to the date of death due to any cause. 24 months after the last subject participating in
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03542461 - Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) Phase 3
Not yet recruiting NCT04073537 - Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer Phase 3
Completed NCT03717155 - Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC Phase 2
Terminated NCT02204345 - A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology Phase 1/Phase 2
Terminated NCT01911325 - Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Phase 1
Withdrawn NCT02924233 - Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer Phase 1/Phase 2
Withdrawn NCT03319316 - Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) Phase 2
Completed NCT04552535 - A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Completed NCT01763788 - A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Not yet recruiting NCT05879484 - Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS Phase 1/Phase 2
Completed NCT02367794 - A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] Phase 3
Recruiting NCT04149691 - Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies Phase 1
Completed NCT03366480 - A Study to Assess the Efficacy and Safety of ABTL0812 Phase 1/Phase 2
Not yet recruiting NCT04266730 - Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab Phase 1
Terminated NCT02109016 - A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Phase 2
Completed NCT02106546 - Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Phase 3
No longer available NCT02475382 - Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen